May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Long-Term Outcomes of Intravitreal Bevacizumab in Patients With Refractory Uveitic Macular Edema
Author Affiliations & Notes
  • T. Yilmaz
    Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts
  • K. Quinones
    Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts
  • R. Cervantes-Castañeda
    Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts
  • C. S. Foster
    Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts
    Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships T. Yilmaz, None; K. Quinones, None; R. Cervantes-Castañeda, None; C.S. Foster, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 4407. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Yilmaz, K. Quinones, R. Cervantes-Castañeda, C. S. Foster; Long-Term Outcomes of Intravitreal Bevacizumab in Patients With Refractory Uveitic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2007;48(13):4407.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the long-term outcomes of intravitreal bevacizumab injection in patients with refractory uveitic macular edema.

Methods:: Chart review of all patients with intraocular inflammation who received intravitreal bevacizumab for refractory macular edema and had at least 6 months of follow-up. Outcome measures included changes in visual acuity and central retinal thickness (CRT), as determined by optical coherence tomography (OCT).

Results:: A total of 29 patients (30 eyes) were identified. Of these, 21 (62%) were female. The mean age of the cohort was 56.6 years. The diagnoses included: anterior uveitis (n=7), intermediate uveitis (n=2), posterior uveitis (n=13), and panuveitis (n=8). Of these, 9 patients had an associated systemic condition, which included juvenile idiopathic arthritis, multiple sclerosis, sarcoidosis, systemic lupus erythematosus, and ulcerative colitis. Initial (pre-treatment) CRT values were less than 300 microns (µm) in 10 (33%) of the cases, between 300 and 400 µm in 7 (23%), and greater than 400 µm in 13 (44%) of cases. Six months after having the injection, CRT values were less than 300 microns (µm) in 16 (53%) of the cases, between 300 and 400 µm in 5 (17%), and greater than 400 µm in 9 (30%) of cases. At this same time point, 13 (43%) eyes achieved acuities equal to or better than 20/40, 10 (33%) eyes saw between 20/50 and 20/100, and 7 (24%) eyes saw less than 20/100. As determined by OCT measurements, there was a net improvement or stabilization in 22 (73%) of the patients. Visual acuity improved or remained stable in 23 (77%) of the subjects.

Conclusions:: Intravitreal bevacizumab appears to be a useful agent for the long-term control of refractory uveitic macular edema.

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • inflammation • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×